Detail akcie Gubra Br/Rg online

Business Summary: Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Gubra A/S revenues increased from DKR120.6M to DKR2.49B. Net income totaled DKR1.76B vs. loss of DKR20.1M. Revenues reflect D&P segment increase from DKR13.1M to DKR2.39B. Net Income reflects Financial income increase from DKR7.8M to DKR121.8M (income), Other operating income decrease from DKR209K (expense) to DKR154K (income). Dividend per share totaled to DKR61.20.